Grant: Master's Award: Canada Graduate Scholarships
McGill University
$17,500.00
Investigating the role of Ras mutations in mediating drug resistance to targeted therapies in cancer
EF 2022-23
Résumé
The cell is equipped with thousands of tools (i.e., proteins) that regulate different processes, guiding the cell and telling it when and where to perform major tasks such as growth, division, and migration. This is done through tightly-regulated signalling pathways, where a chain of regulators turn one another on or off. One example of this is the Mitogen-Activated Protein Kinase (MAPK) pathway, an important pathway that promotes cell growth and survival. However, mutations in a gene called BRAF, an important mediator in MAPK signalling, frequently occur in many cancers. These mutations ramp up MAPK signalling, causing cells to divide rapidly and uncontrollably – providing the conditions needed to form tumors. There are many different types of BRAF mutations which are separated into Classes 1, 2, and 3. Current treatments involve the use of targeted therapies called inhibitors, which block the activity of specific MAPK proteins. While these treatments have shown promising results in people with Class 1 BRAF mutations, those with Class 2 or 3 mutations don’t respond as well to these targeted therapies. This suggests that these tumor cells find alternative ways to resist treatment. In fact, mutations in RAS, another important MAPK player, often occur alongside Class 2/3 BRAF mutations and have been linked to even poorer responses to treatment. Thus, the purpose of my research project is to gain a better understanding of how RAS mutations might be supporting drug resistance in Class 2/3 BRAF mutants, and to discover the key elements involved in facilitating this process. Ultimately, this may allow us to find new targets that can make these tumors vulnerable to new targeted therapies that will lead to better outcomes for patients with all classes of BRAF mutant cancers.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
488144
Name
Mukonoweshuro Chantel L
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Investigating the role of Ras mutations in mediating drug resistance to targeted therapies in cancer
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Cancer; Fbxo42; Functional Genomics; Mapk Inhibition; Mapk Signalling; Non-V600 Braf Mutations; Proto-Oncogenes; Ras Mutations; Targeted Therapies; Therapeutic Resistance
Abstract
The cell is equipped with thousands of tools (i.e., proteins) that regulate different processes, guiding the cell and telling it when and where to perform major tasks such as growth, division, and migration. This is done through tightly-regulated signalling pathways, where a chain of regulators turn one another on or off. One example of this is the Mitogen-Activated Protein Kinase (MAPK) pathway, an important pathway that promotes cell growth and survival. However, mutations in a gene called BRAF, an important mediator in MAPK signalling, frequently occur in many cancers. These mutations ramp up MAPK signalling, causing cells to divide rapidly and uncontrollably – providing the conditions needed to form tumors. There are many different types of BRAF mutations which are separated into Classes 1, 2, and 3. Current treatments involve the use of targeted therapies called inhibitors, which block the activity of specific MAPK proteins. While these treatments have shown promising results in people with Class 1 BRAF mutations, those with Class 2 or 3 mutations don’t respond as well to these targeted therapies. This suggests that these tumor cells find alternative ways to resist treatment. In fact, mutations in RAS, another important MAPK player, often occur alongside Class 2/3 BRAF mutations and have been linked to even poorer responses to treatment. Thus, the purpose of my research project is to gain a better understanding of how RAS mutations might be supporting drug resistance in Class 2/3 BRAF mutants, and to discover the key elements involved in facilitating this process. Ultimately, this may allow us to find new targets that can make these tumors vulnerable to new targeted therapies that will lead to better outcomes for patients with all classes of BRAF mutant cancers.
Competitiondate
202212
Approvedterm2
1 yr 0 mth
Pinamesdelim
Mukonoweshuro, Chantel L
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~